ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 609

Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort

Clementina López-Medina1, Anna Moltó 2, Pascal Claudepierre 3 and Maxime Dougados 4, 1Cochin Hospital, Rheumatology Department, Paris, France, 2Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 3Rheumatology, CHU Henri Mondor Créteil, Paris, France, 4Cochin Hospital, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, non-radiographic and phenotypes

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: There is still a debate concerning the concept of non-radiographic (nr-axSpA) axial Spondyloarthritis (e.g. to consider it as a distinct entity from r-axSpA (Ankylosing Spondylitis) or to consider it as the same disease with different phenotypical presentations). This study aims to compare clinical manifestations and burden of disease between r-axSpA and nr-axSpA over 5 years of follow-up in the DESIR cohort.

Methods: Patients from the DESIR cohort with x-ray sacroiliac joints available at baseline and who did not abandon the study because of different diagnosis than axSpA were included. A unilateral rating of “obvious sacroiliitis” according to the local reader (either a radiologist or a rheumatologist) was considered sufficient to be classified as r-axSpA. The incidence of a new episode of peripheral and extra-rheumatological manifestations between r-axSpA vs. nr-axSpA was assessed using incidence/100 person-years, incidence rate ratio and cox regressions adjusted for sex, age and TNF blockers (TNFb) intake. Mean values of c-reactive protein (CRP), patient reported outcomes (PROs) and days of sick leave over 5 years of follow-up were assessed using mixed models with random effects adjusted for sex, age, TNFb intake and baseline values. Disease-modifying drugs (DMARDs) initiation were also evaluated adjusted for CRP mean levels. 

Results: In total 669 patients were included, of whom 185 (27.7%) and 484 (72.3%) were classified as r-axSpA and nr-axSpA, respectively. At baseline, r-axSpA patients showed significant higher prevalence of males (59.5% vs. 41.7%), smokers (44.0% vs. 34.2%), lower prevalence of peripheral enthesitis (47.6% vs. 60.1%) and lower mean age (31.3±8.9 vs. 34.5±8.4 years) than nr-axSpA. Table 1 shows baseline and 5 years-follow up prevalence, as well as the incidence of new cases of peripheral and extra-rheumatological manifestations. Only peripheral arthritis showed significant lower incidence among r-axSpA patients (2.40 vs. 4.22 new cases/100 person-years, incidence rate ratio 0.57 (95%CI 0.33-0.99)). However, adjusting for age, sex and TFNb intake, cox regressions did not show significant differences in the development of peripheral and extra-rheumatological manifestations between the two groups. Crude mixed models (Table 2) showed significant higher disease activity (BASDAI), poorer quality of life (SF-36 questionnaire) and higher mean days of sick leave over time among nr-axSpA patients. However, these differences disappeared when adjusting for confounders (see Table 2). r-axSpA group showed significant higher incidence of TNFb initiation (14.77 vs. 9.26 new first prescriptions/100 person-years) than nr-axSpA group, with a HR of 1.56 (95%CI 1.17-2.06) adjusted for sex, age and CRP mean levels.

Conclusion: r-axSpA and nr-axSpA patients showed minor differences at baseline. However, they seem to behave similarly over time, since the incidence of peripheral and extra-rheumatological manifestations as well as the burden of disease development remained similar when adjusted for confounders. Only peripheral arthritis seemed to be more incident among nr-axSpA group, while TNFb was most frequently used by r-axSpA patients.

Table 1: Prevalence and incidence of peripheral and extra-rheumatological manifestations.
*p-value <0.05 between r-axSpA and nr-axSpA

Table 2: Mixed model with random effects to compare burden of disease over 5 years of follow up.
Mean -SD- represent the mean value over 5 years of follow-up.


Disclosure: C. López-Medina, None; A. Moltó, None; P. Claudepierre, Janssen, 8; M. Dougados, AbbVie, 2, 5, 8, Amgen, 5, Biogen, 5, BMS, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, Merck, 2, 5, Merck Inc, 2, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8.

To cite this abstract in AMA style:

López-Medina C, Moltó A, Claudepierre P, Dougados M. Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/baseline-characteristics-and-natural-history-of-radiographic-versus-non-radiographic-axial-spondyloarthritis-5-years-follow-up-of-the-desir-cohort/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-characteristics-and-natural-history-of-radiographic-versus-non-radiographic-axial-spondyloarthritis-5-years-follow-up-of-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.